04:49 PM EDT, 03/15/2024 (MT Newswires) -- Legend Biotech ( LEGN ) said a US Food and Drug Administration advisory panel recommended to use an immunotherapy developed by the company and Johnson & Johnson ( JNJ ) be expanded to more patients with relapsed or refractory multiple myeloma than its current indication.

The FDA's Oncologic Drugs Advisory Committee voted 11-to-0 on Friday to recommend the full agency allow the use of Carvykti cellular therapy in patients with plasma cancer who have received as few as one prior treatment.